Mutant TP53 shapes the immune landscape of the TME by down-regulating MHC-1/II expression and T cell infiltration,9 decitabine treatment increased ERV expression, IFN production, and mediated viral mimicry anti-tumor immunity, which is why, TP53mut DLBCL, resistant to R-CHOP, could be eliminated by decitabine combined with chemotherapy (DR-CHOP). Here, TP53 is linked to neoplasm.